Literature DB >> 25248500

The role of epoxide hydrolases in health and disease.

Ahmed A El-Sherbeni1, Ayman O S El-Kadi.   

Abstract

Epoxide hydrolases (EH) are ubiquitously expressed in all living organisms and in almost all organs and tissues. They are mainly subdivided into microsomal and soluble EH and catalyze the hydration of epoxides, three-membered-cyclic ethers, to their corresponding dihydrodiols. Owning to the high chemical reactivity of xenobiotic epoxides, microsomal EH is considered protective enzyme against mutagenic and carcinogenic initiation. Nevertheless, several endogenously produced epoxides of fatty acids function as important regulatory mediators. By mediating the formation of cytotoxic dihydrodiol fatty acids on the expense of cytoprotective epoxides of fatty acids, soluble EH is considered to have cytotoxic activity. Indeed, the attenuation of microsomal EH, achieved by chemical inhibitors or preexists due to specific genetic polymorphisms, is linked to the aggravation of the toxicity of xenobiotics, as well as the risk of cancer and inflammatory diseases, whereas soluble EH inhibition has been emerged as a promising intervention against several diseases, most importantly cardiovascular, lung and metabolic diseases. However, there is reportedly a significant overlap in substrate selectivity between microsomal and soluble EH. In addition, microsomal and soluble EH were found to have the same catalytic triad and identical molecular mechanism. Consequently, the physiological functions of microsomal and soluble EH are also overlapped. Thus, studying the biological effects of microsomal or soluble EH alterations needs to include the effects on both the metabolism of reactive metabolites, as well as epoxides of fatty acids. This review focuses on the multifaceted role of EH in the metabolism of xenobiotic and endogenous epoxides and the impact of EH modulations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248500     DOI: 10.1007/s00204-014-1371-y

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  17 in total

1.  Hepatic transcriptomic alterations for N,N-dimethyl-p-toluidine (DMPT) and p-toluidine after 5-day exposure in rats.

Authors:  June K Dunnick; Keith R Shockley; Daniel L Morgan; Amy Brix; Gregory S Travlos; Kevin Gerrish; J Michael Sanders; T V Ton; Arun R Pandiri
Journal:  Arch Toxicol       Date:  2016-09-16       Impact factor: 5.153

2.  Walnuts change lipoprotein composition suppressing TNFα-stimulated cytokine production by diabetic adipocyte.

Authors:  Kamil Borkowski; Sun J Yim; Roberta R Holt; Robert M Hackman; Carl L Keen; John W Newman; Gregory C Shearer
Journal:  J Nutr Biochem       Date:  2019-03-28       Impact factor: 6.048

Review 3.  Microsomal epoxide hydrolase 1 (EPHX1): Gene, structure, function, and role in human disease.

Authors:  Radka Václavíková; David J Hughes; Pavel Souček
Journal:  Gene       Date:  2015-07-26       Impact factor: 3.688

4.  Mesoderm-specific transcript localization in the ER and ER-lipid droplet interface supports a role in adipocyte hypertrophy.

Authors:  Igor Prudovsky; Rea P Anunciado-Koza; Chester G Jacobs; Doreen Kacer; Matthew E Siviski; Robert A Koza
Journal:  J Cell Biochem       Date:  2017-12-04       Impact factor: 4.429

5.  Development of potent inhibitors of the human microsomal epoxide hydrolase.

Authors:  Bogdan Barnych; Nalin Singh; Sophie Negrel; Yue Zhang; Damien Magis; Capucine Roux; Xiude Hua; Zhewen Ding; Christophe Morisseau; Dean J Tantillo; Justin B Siegel; Bruce D Hammock
Journal:  Eur J Med Chem       Date:  2020-03-13       Impact factor: 6.514

6.  Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.

Authors:  Francesco Dalle Vedove; Cristiano Fava; Houli Jiang; Giovanni Zanconato; John Quilley; Matteo Brunelli; Valeria Guglielmi; Gaetano Vattemi; Pietro Minuz
Journal:  J Hypertens       Date:  2016-07       Impact factor: 4.844

7.  Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney.

Authors:  Jinlan Luo; Shuiqing Hu; Menglu Fu; Liman Luo; Yuanyuan Li; Wenhua Li; Yueting Cai; Ruolan Dong; Yan Yang; Ling Tu; Xizhen Xu
Journal:  J Biol Chem       Date:  2021-04-14       Impact factor: 5.157

8.  EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence.

Authors:  Jeremie Gautheron; Christophe Morisseau; Wendy K Chung; Jamila Zammouri; Martine Auclair; Genevieve Baujat; Emilie Capel; Celia Moulin; Yuxin Wang; Jun Yang; Bruce D Hammock; Barbara Cerame; Franck Phan; Bruno Fève; Corinne Vigouroux; Fabrizio Andreelli; Isabelle Jeru
Journal:  Elife       Date:  2021-08-03       Impact factor: 8.140

Review 9.  Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.

Authors:  Cheng-Peng Sun; Xin-Yue Zhang; Christophe Morisseau; Sung Hee Hwang; Zhan-Jun Zhang; Bruce D Hammock; Xiao-Chi Ma
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

Review 10.  Regulation of cardiovascular biology by microsomal epoxide hydrolase.

Authors:  Matthew L Edin; Darryl C Zeldin
Journal:  Toxicol Res       Date:  2021-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.